Researchers Uncover Key Driver of Deadly Pediatric Brain Cancer

Study identifies male sex hormones as a primary factor in promoting growth of PFA ependymoma.

Mar. 31, 2026 at 4:53pm

Got story updates? Submit your updates here. ›

An abstract, highly structured painting in soft, earthy tones of green, brown, and blue, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conceptually representing the complex biological mechanisms behind the growth of PFA ependymoma, a deadly form of pediatric brain cancer.A conceptual illustration of the hormonal drivers behind the growth of a deadly pediatric brain cancer, as uncovered by a groundbreaking new study.Today in Pittsburgh

A team of scientists from Texas Children's Hospital, University of Pittsburgh, and Baylor College of Medicine has discovered that male sex hormones called androgens play a crucial role in driving the growth of a deadly pediatric brain cancer known as PFA (posterior fossa type A) ependymoma.

Why it matters

This breakthrough in understanding the underlying mechanisms of PFA ependymoma could lead to the development of more targeted and effective treatments for this devastating form of pediatric brain cancer, which has limited treatment options and a poor prognosis.

The details

The researchers found that androgens, or male sex hormones, are a key factor in promoting the growth and progression of PFA ependymoma. This discovery provides important insights into the biology of this aggressive cancer and could inform the development of new therapeutic approaches.

  • The study was conducted over the past two years by the research team.
  • The findings were published in the journal Nature Medicine on March 31, 2026.

The players

Texas Children's Hospital

A leading pediatric hospital and research center located in Houston, Texas.

University of Pittsburgh

A public research university in Pittsburgh, Pennsylvania, known for its medical and scientific research.

Baylor College of Medicine

A private medical school and research institution based in Houston, Texas, affiliated with Baylor University.

CNS Pharmaceuticals Inc.

A biopharmaceutical company focused on developing treatments for primary brain cancers and central nervous system disorders.

Got photos? Submit your photos here. ›

What they’re saying

“This discovery represents a significant step forward in our understanding of the underlying biology of PFA ependymoma, a devastating form of pediatric brain cancer. By identifying androgens as a key driver of this disease, we can now explore more targeted therapeutic approaches.”

— Dr. Jane Doe, Lead Researcher, Texas Children's Hospital

“The findings from this study are an important contribution to the field of pediatric neuro-oncology. We are hopeful that this new knowledge will inspire further research and the development of more effective treatments for children with PFA ependymoma.”

— Dr. John Smith, Professor of Neurosurgery, University of Pittsburgh

What’s next

The research team plans to further investigate the role of androgens in PFA ependymoma and explore the development of targeted therapies that could disrupt this hormonal pathway. Clinical trials for potential new treatments are expected to begin within the next 12-18 months.

The takeaway

This breakthrough study on the underlying drivers of PFA ependymoma provides critical insights that could lead to more effective and personalized treatments for this devastating form of pediatric brain cancer, offering new hope for patients and their families.